

# Recombinant laminin $\alpha 5$ LG1-3 domains support the stemness of human mesenchymal stem cells

SUJIN LEE<sup>1\*</sup>, DONG-SUNG LEE<sup>2\*</sup> and JUN-HYEOG JANG<sup>1</sup>

<sup>1</sup>Department of Biochemistry, College of Medicine, Inha University, Incheon 22212;

<sup>2</sup>College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea

Received April 23, 2020; Accepted November 24, 2020

DOI: 10.3892/etm.2020.9597

**Abstract.** The extracellular matrix components laminin and elastin serve key roles in stem cell therapy. Elastin-like polypeptides (ELPs), derived from a soluble form of elastin, affect the proliferation and differentiation of various types of cells. In the present study, a novel protein was designed containing globular domains 1-3 of laminin  $\alpha 5$  (L $\alpha$ 5LG1-3) fused to ELPs (L $\alpha$ 5LG1-3/ELP). L $\alpha$ 5LG1-3/ELP was expressed in *Escherichia coli* and displayed a molecular size of ~70 kDa on 12% SDS-polyacrylamide gels. The cellular activities, such as cellular adhesion (adhesion assay) and proliferation (MTT cytotoxicity assay), of human mesenchymal stem cells (hMSCs) treated with 1  $\mu$ g/ml of L $\alpha$ 5LG1-3/ELP were enhanced compared with those of untreated cells. Additionally, the number of undifferentiated hMSCs and their degree of stemness were assessed based on the gene expression levels of the stem cell markers cluster differentiation 90 (CD90), endoglin (CD105) and CD73. The expression levels of these markers were upregulated by 2.42-, 2.29- and 1.92-fold, respectively, in the hMSCs treated with L $\alpha$ 5LG1-3/ELP compared with the levels in untreated controls. Thus, L $\alpha$ 5LG1-3/ELP may be used to enhance the viability of hMSCs and preserve their undifferentiated state, whereby the clinical applications of hMSCs may be improved.

## Introduction

One of the key treatments in regenerative medicine is stem cell therapy. Thus, the maintenance of stem cells is essential. Maintenance of the undifferentiated state and proliferation activity of stem cells is essential to sustain their functionality (1). It has been hypothesized that this requirement can

be met by mimicking the *in vivo* extracellular matrix (ECM) configuration, thereby modulating the activity of stem cells *in vitro* (2). The principle behind this hypothesis is that the ECM not only functions as structural support for stem cells *in vivo* but also provides biochemical cues for their maintenance versus directed differentiation (3).

Basement membranes (BMs) are a subgroup of the ECM that is necessary for cell differentiation during early developmental processes. In addition, BMs are critical for the formation and maintenance of mature tissues (4,5). Laminin, one of the components of BMs, consists of three genetically distinct subunits called  $\alpha$ ,  $\beta$  and  $\gamma$  chains, which are assembled into cross-shaped molecules (6,7). At present, 5 $\alpha$ , 3 $\beta$  and 3 $\gamma$  chains, as well as at least 16 different trimeric laminin isoforms are known in humans and mice each (8). Laminin-mediated cell attachment and cellular behavior are achieved by five different  $\alpha$  chains. Among them, laminin  $\alpha 5$  (L $\alpha$ 5) plays a key role during embryogenesis. L $\alpha$ 5, expressed in the inner cell mass of the blastocyst, supports the self-renewal of embryonic stem cells (7,9). L $\alpha$ 5-knockout mouse or zebrafish models have severe developmental defects, demonstrating the effect of L $\alpha$ 5 on stem cell maintenance and embryonic development (10). Most of the cellular binding regions of laminins are primarily located in the C-terminal large globular (G) domain of the protein. The G domain consists of only the laminin  $\alpha$  chain and is subdivided into five homologous LG domains (4,11). LG domains are important for interaction with cells (12). LG1, LG2 and LG3 are the first three of the LG domains, assembled into a clover-leaf arrangement to form the putative binding sites of laminin-binding integrin (11). LG1-3 domains of the  $\alpha 5$  chain comprise cell-binding sites, which is mediated by integrins  $\alpha 3\beta 1$ ,  $\alpha 6\beta 1$  and  $\alpha 6\beta 4$ . LG4 domain of the  $\alpha 5$  chain binds to  $\alpha$ -dystroglycan and heparin (12-14).

Elastin is an important ECM protein found abundantly in blood vessels and serves as a biomechanical and physiological signal for cells (15). The soluble form of elastin, tropoelastin, is primarily located in elastic tissues. It has been reported to promote the proliferation of hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) (16). Additionally, it is often used in the form of cross-linked gel fibers or injectable scaffolds for tissue engineering and drug delivery (17). Elastin-like polypeptides (ELPs) are recombinant peptide polymers composed of VPGXG pentapeptides (found in tropoelastin), where X stands for any amino acid residue except

---

*Correspondence to:* Professor Jun-Hyeog Jang, Department of Biochemistry, College of Medicine, Inha University, 100 Inha, Michuhol, Incheon 22212, Republic of Korea  
E-mail: juhjang@inha.ac.kr

\*Contributed equally

**Key words:** laminin, elastin, elastin-like polypeptide, cell adhesion, cell proliferation, mesenchymal stem cells, stemness, stem cell therapy

proline (18). ELPs exhibit biocompatibility that is similar to elastin in terms of mechanical and viscoelastic properties. ELPs effectively modulate the migration, proliferation, and differentiation of various type of mammalian cells (19). These polypeptides can be genetically engineered to modulate their structural and biological properties and exhibit an inverse phase transition behavior in response to the changes in their solutions (20). Recombinant ELPs have been expressed in *E. coli* and subsequently purified through a separation process known as inverse transition cycling (ITC) (21).

Human MSCs (hMSCs) are pluripotent stem cells that can differentiate both *in vitro* and *in vivo*. In particular, it is known that hMSCs can differentiate into the mesenchymal lineage, forming bone, cartilage, adipose, and muscle cells. These stem cells can be isolated from cord blood, placental fluids, and multiple adult tissues, such as bone marrow, adipose tissue, skeletal muscle, and connective tissue (22-27). Previously, we have shown that a recombinant human laminin  $\alpha 2$  LG1-3 promotes hMSCs physiology *in vitro*, including cell adhesion, proliferation, and stemness (28). In this study, we fused the coding sequence of ELP to laminin $\alpha 5$  LG1-3 domains and examined the cellular effects of this fusion construct (L $\alpha 5$ LG1-3/ELP) on hMSCs.

## Materials and methods

**Construction and purification of L $\alpha 5$ LG1-3/ELP fusion protein.** L $\alpha 5$ LG1-3 coding sequence containing integrin-binding modules LG1-LG3 of laminin  $\alpha 5$  (L $\alpha 5$ ) and ELP coding sequence were synthesized (Genotech).

Based on the characteristics of ELP guest residues (19-21), ELP coding sequence was designed by inserting Val, Leu, and Gly (ratio of 17:4:9) into ELP guest residue position. The full-length ELP(V17L4G9-30) coding sequence containing Val, Leu, and Gly in the fourth guest residue (Xaa) (Val-Pro-Gly-Xaa-Gly) of the pentapeptide repeat is VPGGG VPGVG VPGGG VPGVG VPGVG VPGGG VPGVG VPGVG VPGGG VPGLG VPGVG VPGVG VPGGG VPGVG VPGLG VPGVG VPGVG VPGGG VPGVG VPGLG VPGVG VPGVG VPGGG VPGVG VPGLG VPGVG VPGVG VPGGG VPGVG VPGGG.

The L $\alpha 5$ LG1-3 construct was double digested with *SacI* and *KpnI* and then cloned into the expression vector pBAD-His (Invitrogen; Thermo Fisher Scientific, Inc.) to construct the pBAD-His-L $\alpha 5$ LG1-3. Next, ELP construct was double digested with *KpnI* and *EcoRI* and then cloned into pBAD-His-L $\alpha 5$ LG1-3 to construct the pBAD-His-L $\alpha 5$ LG1-3/ELP.

The recombinant pBAD-His-L $\alpha 5$ LG1-3/ELP was transformed into *E. coli* TOP10 cells through heat shock at 42°C. A single colony was selected and inoculated into 20 ml Luria-Bertani (LB) media (LPS Solution) containing 100  $\mu$ g/ml ampicillin (LB-Amp) overnight at 37°C. This overnight culture was then mixed with 1 liter LB medium and incubated until the OD<sub>600</sub> reached 0.4. Subsequently, L-Arabinose was added to a final concentration of 0.1% (w/v), and the culture temperature was decreased to 20°C. After 6 h of induction, bacterial cells were pelleted by centrifugation at 4°C and 6000 x g for 15 min. The pellet was resuspended in sodium chloride-Tris-EDTA buffer and then lysed by sonication. The lysate was obtained by centrifugation at 13,000 x g and 4°C for 20 min. To obtain L $\alpha 5$ LG1-3/ELP, the supernatant was purified through ITC.

Briefly, the supernatant was transferred into fresh tube with 3 M NaCl pre-heated to 40°C, followed by centrifugation at 40°C to obtain the L $\alpha 5$ LG1-3/ELP pellet. After discard of supernatant containing soluble L $\alpha 5$ LG1-3/ELP, and the pellet was re-solubilized in cold phosphate-buffered saline. The resulting solution was centrifuged at 4°C to remove any insoluble protein, and the supernatant, containing pure L $\alpha 5$ LG1-3/ELP, was kept. The purity of this solution was analyzed through 12% SDS-PAGE, followed by Coomassie blue staining. Additionally, western blots analysis was performed using a peroxidase-conjugated monoclonal anti-polyhistidine antibody (His antibody, sc-8036 HRP; Santa Cruz Biotechnology, Inc.) diluted at 1:1,000 to assess the expression of L $\alpha 5$ LG1-3/ELP. The size of the immunodetected protein was determined based on the pre-stained protein markers (Elpis Biotech) electrophoresed in parallel lanes.

**Cell culture.** Primary hMSCs were kindly provided by Dr Sung-Won Kim (St. Mary's Hospital, the Catholic University of Korea) (29,30). The cells were maintained in a humidified incubator at 37 °C with 5% CO<sub>2</sub> and cultured in the growth medium (minimum essential medium,  $\alpha$ -modification) ( $\alpha$ -MEM) (Welgene) containing 10% fetal bovine serum (Welgene), 100  $\mu$ g/ml streptomycin, 100 U/ml penicillin, and 0.25  $\mu$ g/ml amphotericin B (Invitrogen; Thermo Fisher Scientific, Inc.). Confluent cells were passaged by trypsinization (0.25% trypsin-EDTA solution for 3 min). Cells were maintained for three passages before use for further cell experiments.

**Adhesion assay.** Cell adhesion assay was carried out using crystal violet. Culture plates were coated with 0, 0.01, 0.05, 0.1, 0.5, 1.0, or 5.0  $\mu$ g/ml of purified L $\alpha 5$ LG1-3/ELP protein for 2 h at 37°C. Following three rinse with Dulbecco's phosphate-buffered saline (DPBS) (Welgene), the plates were blocked with 0.5% (w/v) bovine serum albumin (BSA) (Gibco; Thermo Fisher Scientific, Inc.) in DPBS for 1 h at 37°C. Subsequently, hMSCs were added (5x10<sup>4</sup> cells/well) and incubated at 37°C for 30 min. Three replicates were performed for each treatment. After incubation, non-attached cells were removed by three rinses with DPBS, and the remaining cells were fixed by incubation in 3.7% formalin solution for 20 min at room temperature. The fixed cells were stained with 0.25% (w/v) crystal violet (Sigma-Aldrich; Merck KGaA) for 30 min at room temperature. Subsequently, they were extensively rinsed with DPBS and then lysed using 2% SDS. The culture plates were read on a microplate reader (BioTek) at 570 nm. Additionally, cell adhesion was monitored with 15 min intervals to confirm the adhesion over time. Cell adhesion activity was normalized relative to uncoated plates.

**MTT cytotoxicity assay.** Twenty-four-well plates were coated with 1  $\mu$ g/ml L $\alpha 5$ LG1-3/ELP protein for 2 h at 37°C and then rinsed three times with DPBS. Subsequently, hMSCs were added (1x10<sup>4</sup> cells/well) and incubated for 7 days at 37°C. Three replicates were performed, and cell proliferation was assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; AMRESCO Inc.) assay, which measures the metabolic activity of viable cells, according to the manufacturer's directions (Promega). Briefly, cells were rinsed three times with DPBS and then incubated with 0.5 ml/well of

Table I. Sequences of the primers used for reverse transcription-quantitative PCR.

Gene	Forward primer	Reverse primer
$\beta$ -actin	5'-TGGCACCCAGCACAATGAAGAT-3'	5'-TACTCCTGCTTGCTGATCCA-3'
CD90	5'-CCAAAGGCTTCTTCTTGCTG-3'	5'-CCACCAAATGTGAAGACGTG-3'
CD105	5'-GAAAATGGAGCTCCTGGTCA-3'	5'-ACCCTTAGCACCAACAGCAC-3'
CD73	5'-CAGTACCAGGGCACTATCTGG-3'	5'-AGTGGCCCCCTTTGCTTTAAT-3'

CD, cluster of differentiation.




Figure 1. Cloning and purification of recombinant La5LG1-3/ELP. (A) cDNA encoding ELP was cloned into the pBAD-HisA-La5LG1-3 expression vector. (B) Molecular weight of the protein was estimated as 70 kDa via western blotting probed using an anti-His6-tag monoclonal antibody. La5LG1-3/ELP, globular domains 1-3 of laminin  $\alpha$ 5/elastin-like polypeptide.

5  $\mu$ g/ml MTT in DPBS for 2 h at 37°C. Afterward, the MTT solution was removed, and the resulting formazan crystals were dissolved in 150  $\mu$ l/well of dimethyl sulfoxide. The plates were read at 570 nm on a microplate reader (BioTek). Data were normalized using the uncoated control.

**Quantitative reverse transcription-polymerase chain reaction (qRT-PCR).** The total RNA of the cell was isolated using the Easy-Spin Total RNA Extraction Kit and then purified following the manufacturer's directions (Intron). The RNA amount and quality were assessed using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.). Next, cDNA was synthesized from 1  $\mu$ g of total RNA by using the High Capacity cDNA Reverse Transcription Kit according to the manufacturer's directions (Applied Biosystems; Thermo Fisher Scientific, Inc.). qRT-PCR was performed using SYBR-Green PCR Master Mix (Toyobo) and the ABI Step One Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR conditions were as follows: 10 min at 95°C and 40 cycles of 95°C for 15 sec and 60°C for 1 min. The gene expression level was normalized to that of  $\beta$ -actin and estimated with the comparative  $C_q$  method (31). Each experiment per sample was performed in triplicate. The primers used are listed in Table I.

**Statistical analysis.** ANOVA followed by a post-hoc Tukey's test was used for comparisons between various groups. Differences between two groups were tested via unpaired Student's t-test: P-value <0.05 was considered significant (\*P<0.05, \*\*P<0.01 and \*\*\*P<0.001). Experiments were repeated three times, and the results are presented as mean  $\pm$  SD.

## Results

**Expression and purification of La5LG1-3/ELP protein.** To make the recombinant La5LG1-3/ELP construct, the La5LG1-3 sequence was inserted into the pPAD-HisA expression vector. Then, the ELP sequence was inserted into the resulting pBAD-His-La5LG1-3 expression vector. The La5LG1-3/ELP fusion protein retained the phase transition property of ELP. Thus, La5LG1-3/ELP could be purified through ITC. The molecular size of La5LG1-3/ELP was estimated at approximately 70 kDa on 12% SDS-polyacrylamide gels stained with Coomassie blue. The expression of La5LG1-3/ELP was verified by western blotting with a peroxidase-conjugated monoclonal anti-polyhistidine antibody specific to the N-terminal His-tag (Fig. 1). Production of this La5LG1-3/ELP protein was well-established and used in subsequent experiments.




Figure 2. Adhesion of human mesenchymal stem cells in plates coated with recombinant  $\text{La5LG1-3/ELP}$ . Attached cells were observed using the crystal violet assay, and the results are expressed as the mean  $\pm$  SD of three independent experiments. \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  vs. control.  $\text{La5LG1-3/ELP}$ , globular domains 1-3 of laminin  $\alpha 5$ /elastin-like polypeptide.




Figure 3. Effect of recombinant  $\text{La5LG1-3/ELP}$  on the proliferation of human mesenchymal stem cells evaluated using MTT assay. The results are expressed as the mean  $\pm$  SD of three independent experiments. \*\*\* $P < 0.001$ .  $\text{La5LG1-3/ELP}$ , globular domains 1-3 of laminin  $\alpha 5$ /elastin-like polypeptide.

*La5LG1-3/ELP promotes the adhesion of hMSCs.* Cell adhesion assay was carried out using crystal violet to determine the effect of  $\text{La5LG1-3/ELP}$  on the adhesion of hMSCs. As shown in Fig. 2 ( $P < 0.001$ ), the attachment of hMSCs was significantly better in the wells coated with  $\text{La5LG1-3/ELP}$  than in the uncoated, control wells. Moreover,  $\text{La5LG1-3/ELP}$  improved the cell adhesion in a dose-dependent manner, with the cell adhesion saturated at 1  $\mu\text{g/ml}$  of  $\text{La5LG1-3/ELP}$ . Therefore,  $\text{La5LG1-3/ELP}$  was used at 1  $\mu\text{g/ml}$  in the subsequent experiments.

*La5LG1-3/ELP enhances the proliferation of hMSCs.* We measured the effect of  $\text{La5LG1-3/ELP}$  on the proliferative activity of hMSCs by using the MTT assay. Toward this end, 24-well plates were coated with  $\text{La5LG1-3/ELP}$ , and hMSCs were incubated in these coated wells for 7 days. Additionally, experiments were conducted in two groups of 0 and 7 days for comparison. After 7 days, the proliferation of hMSCs increased 1.45-fold ( $P < 0.001$ ; Fig. 3) in the coated well compared with the proliferation in the




Figure 4. Recombinant  $\text{La5LG1-3/ELP}$  enhances the stemness of human mesenchymal stem cells. The mRNA expression levels of CD90, CD105 and CD73 were measured using reverse transcription-quantitative PCR. The mRNA expression levels of each gene were normalized relative to the mRNA levels of  $\beta$ -actin, which served as an internal control. The results are expressed as the mean  $\pm$  SD of three independent experiments. \*\* $P < 0.01$ .  $\text{La5LG1-3/ELP}$ , globular domains 1-3 of laminin  $\alpha 5$ /elastin-like polypeptide; CD, cluster of differentiation.

controls (uncoated wells). This result demonstrated that  $\text{La5LG1-3/ELP}$  enhances the proliferation of hMSCs.

*La5LG1-3/ELP helps maintain the stemness of hMSCs.* qRT-PCR was performed to confirm that  $\text{La5LG1-3/ELP}$  maintains stemness of hMSCs at the gene expression level. The distinctive stem cell surface marker genes cluster differentiation 90 ( $CD90$ ), endoglin ( $CD105$ ) and  $CD73$  were chosen. The mRNA levels of these markers in hMSCs grown with or without  $\text{La5LG1-3/ELP}$  for 7 days are presented in Fig. 4. The gene expression levels of  $CD90$ ,  $CD105$  and  $CD73$  were upregulated in the presence of  $\text{La5LG1-3/ELP}$  compared with the levels in the uncoated control wells.

## Discussion

Cells must interact with the ECM because it supports many cellular activities, including adhesion, proliferation, and differentiation (32). Laminin and elastin are two ECM proteins predominantly present in the BMs of most tissues in humans (33). The major multifunctional components of the ECM include the followings: i) Laminin is one of the glycoproteins and a major factor affecting cell attachment, proliferation, differentiation and survival. The five globular domains of the  $\alpha$ -chain, LG domains, are known to have a critical effect on cells by binding to integrins. ii) Elastin affects the biomechanical and physiological properties of cells (32,33). In this work, we engineered a novel fusion protein composed of LG1-3 domains laminin  $\alpha 5$  chain and ELPs, recombinant forms of elastin.

The  $\text{La5LG1-3/ELP}$  fusion protein was purified through ITC, based on the inverse phase transition properties of ELP. As shown in Fig. 1, the total molecular weight of the recombinant protein was estimated at approximately 70 kDa by performing western blot analysis with and antibody that detects the amino-terminal His-tag. The production of the recombinant protein was successful, and the presence of  $\text{La5LG1-3/ELP}$  was determined by protein identification. The major BM proteins laminins, exert biological activities, such as promoting cell attachment, differentiation, and migration, as well as angiogenesis and formation of neurite outgrowths (5,6).

Integrins are the most characteristic laminin receptors that the diverse biological activities of laminins. Moreover, interactions of cells with laminins are crucial to cellular adhesion (4,33).

The hMSCs are pluripotent stem cells that can differentiate into mesenchymal lineages (22,23). To assess the effect of L $\alpha$ 5LG1-3/ELP on the adhesion of hMSCs, we performed the cell adhesion assay by using crystal violet. L $\alpha$ 5LG1-3/ELP enhanced the adhesion of hMSCs in a dose-dependent manner, with saturation at 1  $\mu$ g/ml. Therefore, L $\alpha$ 5LG1-3/ELP, was used at the concentration of 1  $\mu$ g/ml for the subsequent experiments (Fig. 2). To further estimate the effect of L $\alpha$ 5LG1-3/ELP on hMSC proliferation, MTT assay was carried out. For this purpose, hMSCs were grown in L $\alpha$ 5LG1-3/ELP coated 24-well plates for 7 days and then used for the assay. In addition, for comparison, experiments were conducted in two groups, 0 day and 7 day. As shown in Fig. 3, after 7 days, the cell proliferation was 1.45-fold higher in the coated plates than in the uncoated controls. Taken together, these results suggest that L $\alpha$ 5LG1-3/ELP improves the proliferation of hMSCs.

It has been reported that hMSCs express CD44, CD71, CD73, CD90 (Thy-1), CD105 (endoglin), and CD271, but not the co-stimulatory molecules CD80, CD86 and CD40, or the hematopoietic markers CD14, CD34 and CD45 (22). In addition, hMSCs express various surface receptors, such as integrin, that bind to the LG1-3 domain of the laminin  $\alpha$ -chain. Therefore, hMSCs are anticipated to bind to recombinant laminin  $\alpha$ 5 LG1-3 (L $\alpha$ 5LG1-3) (27). To investigate the effect of L $\alpha$ 5LG1-3/ELP on the maintenance of the stemness properties of hMSCs, the gene expression levels of the stem cell surface markers CD73, CD90 and CD105 were measured through qRT-PCR. Total RNA was isolated from cells cultured in L $\alpha$ 5LG1-3/ELP coated plates for 7 days, cDNA was synthesized and surface markers were examined, and CD90, CD105, and CD73 were stem cell surface markers that are expressed by hMSCs at varying levels (34). CD90 is a stem cell surface-anchoring glycoprotein that plays a key role in cell motility, and is essential for stem cell growth and differentiation (35,36). CD90 expression at high levels is associated with the undifferentiated state of MSCs (37). CD105, also called SH2, is a component of a receptor complex that transforming growth factor- $\beta$  (TGF- $\beta$ ), which modulates stem cell migration, proliferation, and differentiation. Additionally, CD105 is also used for purifying hMSCs through an immunoselection method. CD105-positive MSCs can differentiate into chondrogenic, osteogenic, and adipogenic lineages (36,38,39). CD73, also termed as ecto-5'-nucleotidase, is a glycosyl phosphatidylinositol-linked membrane protein found on the surface of multiple cell types. It is found on the surfaces of hematopoietic and mesenchymal stem cells and functions in numerous physiological processes in various tissues (40-42). In addition, CD73 is known to modulates epithelial-mesenchymal stem cell transition and stemness in ovarian cancer initiating cells (43). As shown in Fig. 4, the expression levels of the surface markers CD90, CD105 and CD73 were 2.42-, 2.29- and 1.92-fold higher, respectively, than the levels in the control. These results indicate that L $\alpha$ 5LG1-3/ELP contributes to maintaining the undifferentiated state of hMSCs. The increase in CD90, CD105 and CD73 levels in hMSCs cultured in L $\alpha$ 5LG1-3/ELP-coated plates suggest that L $\alpha$ 5LG1-3/ELP supports the stemness properties of hMSCs. In order to further

clarify the effect of L $\alpha$ 5LG1-3/ELP, and experiment at the protein level such as western blot will be performed later.

In conclusion, L $\alpha$ 5LG1-3/ELP maintains the undifferentiated state of hMSCs and promotes their adhesion, proliferation, and stemness. Therefore, L $\alpha$ 5LG1-3/ELP can potentially be used during MSC therapy to enhance the viability of these stem cells and their maintenance at the undifferentiated state. Hence, *in vivo* experiments with recombinant laminin are required.

### Acknowledgements

Not applicable.

### Funding

The present study was supported by the National Research Foundation of Korea grant funded by the Korean government (grant no. NRF-2020R1A2C1009533) and Inha University Research Grant.

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Authors' contributions

SL, DSL and JHJ conceptualized the study. SL and JHJ analyzed the data, performed the experiments and curated the data. SL, DSL and JHJ prepared and wrote the original manuscript, reviewed and edited the manuscript, including the figures. JHJ supervised the study. All authors read and approved the final manuscript.

### Ethics approval and consent to participate

The human mesenchymal stem cells were isolated from tissues discarded during surgery. The study was conducted with the written informed consent of the subject who provided the tissue. The isolation of human mesenchymal stem cells from tissues was approved by the Institutional Review Board of the Catholic University of Korea, St. Mary's Hospital (approval no. KC08TISS034). All cells were provided by Dr Sung-Won Kim (St. Mary's Hospital, the Catholic University of Korea).

### Patient consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

1. Molofsky AV, Pardal R and Morrison SJ: Diverse mechanisms regulate stem cell self-renewal. *Curr Opin Cell Biol* 16: 700-707, 2004.
2. Rozario T and DeSimone DW: The extracellular matrix in development and morphogenesis: A dynamic view. *Dev Biol* 341: 126-140, 2010.

3. Mahapatra C, Kim JJ, Lee JH, Jin GZ, Knowles JC and Kim HW: Differential chondro- and osteo-stimulation in three-dimensional porous scaffolds with different topological surfaces provides a design strategy for biphasic osteochondral engineering. *J Tissue Eng*: Jan 31, 2019 (Epub ahead of print). doi: 10.1177/2041731419826433.
4. Suzuki N, Yokoyama F and Nomizu M: Functional sites in the laminin alpha chains. *Connect Tissue Res* 46: 142-152, 2005.
5. Miner JH and Yurchenco PD: Laminin functions in tissue morphogenesis. *Annu Rev Cell Dev Biol* 20: 255-284, 2004.
6. Patarroyo M, Tryggvason K and Virtanen I: Laminin isoforms in tumor invasion, angiogenesis and metastasis. *Semin Cancer Biol* 12: 197-207, 2002.
7. Rohn F, Kordes C, Castoldi M, Götze S, Poschmann G, Stühler K, Herebian D, Benk AS, Geiger F, Zhang T, *et al*: Laminin-521 promotes quiescence in isolated stellate cells from rat liver. *Biomaterials* 180: 36-51, 2018.
8. Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, Engel J, Engvall E, Hohenester E and Jones JC: A simplified laminin nomenclature. *Matrix Biol* 24: 326-332, 2005.
9. Klaffky E, Williams R, Yao CC, Ziober B, Kramer R and Sutherland A: Trophoblast-specific expression and function of the integrin alpha 7 subunit in the peri-implantation mouse embryo. *Dev Biol* 239: 161-175, 2001.
10. Miner JH, Cunningham J and Sanes JR: Roles for laminin in embryogenesis: Exencephaly, syndactyly, and placentopathy in mice lacking the laminin alpha5 chain. *J Cell Biol* 143: 1713-1723, 1998.
11. Navdaev A and Eble JA: Components of cell-matrix linkage as potential new markers for prostate cancer. *Cancers (Basel)* 3: 883-896, 2011.
12. Yu H and Talts JF: Beta1 integrin and alpha-dystroglycan binding sites are localized to different laminin-G-domain-like (LG) modules within the laminin alpha5 chain G domain. *Biochem J* 371: 289-299, 2003.
13. Ido H, Harada K, Futaki S, Hayashi Y, Nishiuchi R, Natsuka Y, Li S, Wada Y, Combs AC, Ervasti JM, *et al*: Molecular dissection of the alpha-dystroglycan- and integrin-binding sites within the globular domain of human laminin-10. *J Biol Chem* 279: 10946-10954, 2004.
14. Nielsen PK, Gho YS, Hoffman MP, Watanabe H, Makino M, Nomizu M and Yamada Y: Identification of a major heparin and cell binding site in the LG4 module of the laminin alpha 5 chain. *J Biol Chem* 275: 14517-14523, 2000.
15. Blit PH, Battiston KG, Woodhouse KA and Santerre JP: Surface immobilization of elastin-like polypeptides using fluorinated surface modifying additives. *J Biomed Mater Res A* 96: 648-662, 2011.
16. Yeo GC and Weiss AS: Soluble matrix protein is a potent modulator of mesenchymal stem cell performance. *Proc Natl Acad Sci USA* 116: 2042-2051, 2019.
17. Annabi N, Mithieux SM, Boughton EA, Ruys AJ, Weiss AS and Dehghani F: Synthesis of highly porous crosslinked elastin hydrogels and their interaction with fibroblasts in vitro. *Biomaterials* 30: 4550-4557, 2009.
18. Meyer DE and Chilkoti A: Genetically encoded synthesis of protein-based polymers with precisely specified molecular weight and sequence by recursive directional ligation: Examples from the elastin-like polypeptide system. *Biomacromolecules* 3: 357-367, 2002.
19. Amruthwar SS and Janorkar AV: In vitro evaluation of elastin-like polypeptide-collagen composite scaffold for bone tissue engineering. *Dent Mater* 29: 211-220, 2013.
20. MacEwan SR and Chilkoti A: Elastin-like polypeptides: Biomedical applications of tunable biopolymers. *Biopolymers* 94: 60-77, 2010.
21. Meyer DE and Chilkoti A: Purification of recombinant proteins by fusion with thermally-responsive polypeptides. *Nat Biotechnol* 17: 1112-1115, 1999.
22. Lotfinegad P, Shamsasenjan K, Movassaghpour A, Majidi J and Baradaran B: Immunomodulatory nature and site specific affinity of mesenchymal stem cells: A hope in cell therapy. *Adv Pharm Bull* 4: 5-13, 2014.
23. Lee DJ, Kwon J, Current L, Yoon K, Zalal R, Hu X, Xue P and Ko CC: Osteogenic potential of mesenchymal stem cells from rat mandible to regenerate critical sized calvarial defect. *J Tissue Eng* 10: 2041731419830427, 2019.
24. Re F, Sartore L, Moulisova V, Cantini M, Almicci C, Bianchetti A, Chinello C, Dey K, Agnelli S, Manfredini C, *et al*: 3D gelatin-chitosan hybrid hydrogels combined with human platelet lysate highly support human mesenchymal stem cell proliferation and osteogenic differentiation. *J Tissue Eng* 10: 2041731419845852, 2019.
25. Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M and Werner C: Mesenchymal stem cells can be differentiated into endothelial cells in vitro. *Stem Cells* 22: 377-384, 2004.
26. Tran TC1: Kimura K, Nagano M, Yamashita T, Ohneda K, Sugimori H, Sato F, Sakakibara Y, Hamada H, Yoshikawa H, *et al*: Identification of human placenta-derived mesenchymal stem cells involved in re-endothelialization. *J Cell Physiol* 226: 224-235, 2011.
27. Wen J, Zhao Z, Tong R, Huang L, Miao Y and Wu J: Prussian blue nanoparticle-labeled mesenchymal stem cells: Evaluation of cell viability, proliferation, migration, differentiation, cytoskeleton, and protein expression in vitro. *Nanoscale Res Lett* 13: 329, 2018.
28. Kim JE, Seo HJ, Lee S and Jang JH: Evaluation of stemness maintenance properties of the recombinant human laminin  $\alpha 2$  LG1-3 domains in human mesenchymal stem cells. *Protein Pept Lett* 26: 785-791, 2019.
29. Hwang SH, Cho HK, Park SH, Lee W, Lee HJ, Lee DC, Park SH, Lim MH, Back SA, Yun BG, *et al*: Characteristics of human turbinate-derived mesenchymal stem cells are not affected by allergic condition of donor. *PLoS One* 10: e0138041, 2015.
30. Hang Pham LB, Yoo YR, Park SH, Back SA, Kim SW, Bjørge I, Mano J and Jang JH: Investigating the effect of fibulin-1 on the differentiation of human nasal inferior turbinate-derived mesenchymal stem cells into osteoblasts. *J Biomed Mater Res A* 105: 2291-2298, 2017.
31. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-Delta Delta C(T)</sup> method. *Methods* 25: 402-408, 2001.
32. Paiva Dos Santos B, Garbay B, Pasqua M, Chevron E, Chinoy ZS, Cullin C, Bathany K, Lecommandoux S, Amédée J, Oliveira H, *et al*: Production, purification and characterization of an elastin-like polypeptide containing the Ile-Lys-Val-Ala-Val (IKVAV) peptide for tissue engineering applications. *J Biotechnol* 298: 35-44, 2019.
33. Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, Guiducci S, Jones S, Jorgensen C, Le Blanc K, *et al*: Immunomodulatory properties of mesenchymal stem cells: A review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. *Arthritis Res Ther* 9: 301, 2007.
34. Hynes RO: Integrins: Bidirectional, allosteric signaling machines. *Cell* 110: 673-687, 2002.
35. Moraes DA, Sibov TT, Pavon LF, Alvim PQ, Bonadio RS, Da Silva JR, Pic-Taylor A, Toledo OA, Marti LC, Azevedo RB, *et al*: A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells. *Stem Cell Res Ther* 7: 97, 2016.
36. Aslan H, Zilberman Y, Kandel L, Liebergall M, Oskouian RJ, Gazit D and Gazit Z: Osteogenic differentiation of noncultured immunisolated bone marrow-derived CD105<sup>+</sup> cells. *Stem Cells* 24: 1728-1737, 2006.
37. Sibov TT, Severino P, Marti LC, Pavon LF, Oliveira DM, Tobo PR, Campos AH, Paes AT, Amaro E Jr, F Gamarra L, *et al*: Mesenchymal stem cells from umbilical cord blood: Parameters for isolation, characterization and adipogenic differentiation. *Cytotechnology* 64: 511-521, 2012.
38. Maleki M, Ghanbarvand F, Reza Behvarz M, Ejtemaei M and Ghadirkhomi E: Comparison of mesenchymal stem cell markers in multiple human adult stem cells. *Int J Stem Cells* 7: 118-126, 2014.
39. Roura S, Farré J, Soler-Botija C, Llach A, Hove-Madsen L, Cairó JJ, Gòdia F, Cinca J and Bayes-Genis A: Effect of aging on the pluripotential capacity of human CD105<sup>+</sup> mesenchymal stem cells. *Eur J Heart Fail* 8: 555-563, 2006.
40. Yu YI, Wang W, Song L, Hu W, Dong C, Pei H, Zhou G and Yue Z: Ecto-5'-nucleotidase expression is associated with the progression of renal cell carcinoma. *Oncol Lett* 9: 2485-2494, 2015.
41. Colgan SP, Eltzschig HK, Eckle T and Thompson LF: Physiological roles for ecto-5'-nucleotidase (CD73). *Purinergic Signal* 2: 351-360, 2006.
42. Zimmermann H: 5'-Nucleotidase: Molecular structure and functional aspects. *Biochem J* 285: 345-365, 1992.
43. Lupia M, Angiolini F, Bertalot G, Freddi S, Sachsenmeier KF, Chisci E, Kutryb-Zajac B, Confalonieri S, Smolenski RT, Giovannoni R, *et al*: CD73 regulates stemness and epithelial-mesenchymal transition in ovarian cancer-initiating cells. *Stem Cell Reports* 10: 1412-1425, 2018.